Critical Care Research and Practice / 2011 / Article / Tab 1

Clinical Study

Impact of a Multimodal Antimicrobial Stewardship Program on Pseudomonas aeruginosa Susceptibility and Antimicrobial Use in the Intensive Care Unit Setting

Table 1

Intensive care unit anti-pseudomonal antibiotic utilization (2003–2010).

20032004200520062007200820092010

Cefepime4.54.018.536.568.592.536.090.5
Ceftazidime90.562.553.038.024.539.023.525.5
Piperacillin-tazobactam87.0124.5127.5115.597.5139.0130.0133.0
Carbapenems30.052.553.060.048.5112. 88.5 78.5
Ciprofloxacin192.5148.057.825.540.066.548.087.0
Gentamicin10.520.540.026.58.517.510.511.0
Tobramycin1.00.542.556.558.048.035.031.0

Data expressed as defined daily dose (DDD) per 1000 patient-days.
The two years with the highest percentage of specific antibiotic use are bolded.
Year with two cycles of this antibiotic in VAP protocol.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.